Skip to main content
Fig. 5 | Cardiovascular Diabetology

Fig. 5

From: Empagliflozin improved systolic blood pressure, endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 rat

Fig. 5

Effect of empagliflozin treatment on the expression level of senescence markers (p53, p21 and p16) in segments of the outer curvature (AOC), an arterial site at low risk, and in those of the inner curvature (AIC) of the aortic arch, an arterial site at high risk, in the lean control and ZSF1 groups as assessed by Western blot analysis. Results are shown as representative immunoblots (upper panels) and corresponding cumulative data (lower panels). Values are shown as mean ± SEM of n = 3–4 per group. *P < 0.05 vs AOC of control group and #P < 0.05 vs AIC of control group and +P < 0.05 vs AOC of Empa group

Back to article page